To report results of the OCARINA I (NCT03972306) Phase Ib, dose-escalation study that assessed ocrelizumab (OCR) safety, tolerability and pharmacokinetic data in patients with relapsing and primary progressive multiple sclerosis (RMS/PPMS), to select the appropriate OCR subcutaneous (SC) dose for OCARINA II.
No takes yet. Share an insight, caveat, or question.
Newsome et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: